Robert Stefanovich Sells 1,659 Shares of Cryoport, Inc. (NASDAQ:CYRX) Stock

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,659 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $10,435.11. Following the sale, the chief financial officer now directly owns 191,419 shares of the company’s stock, valued at $1,204,025.51. The trade was a 0.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $6,129.28.

Cryoport Price Performance

NASDAQ:CYRX opened at $5.84 on Thursday. The business’s 50-day simple moving average is $6.92 and its two-hundred day simple moving average is $7.42. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $20.11. The stock has a market cap of $291.47 million, a PE ratio of -1.73 and a beta of 1.67. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. During the same period last year, the business posted ($0.29) EPS. As a group, analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Cryoport

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Quest Partners LLC increased its holdings in Cryoport by 168.5% in the 3rd quarter. Quest Partners LLC now owns 29,083 shares of the company’s stock valued at $236,000 after acquiring an additional 18,252 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Cryoport during the third quarter valued at about $326,000. Intech Investment Management LLC bought a new stake in shares of Cryoport in the third quarter worth about $105,000. Charles Schwab Investment Management Inc. lifted its position in shares of Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after buying an additional 2,226 shares in the last quarter. Finally, Algert Global LLC boosted its stake in Cryoport by 282.7% during the third quarter. Algert Global LLC now owns 247,483 shares of the company’s stock valued at $2,007,000 after buying an additional 182,808 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CYRX. Guggenheim assumed coverage on Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research report on Wednesday, March 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Cryoport currently has an average rating of “Moderate Buy” and an average target price of $11.50.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.